julia.endo said:Orforglipron is the more interesting oral story because it is not a peptide at all.
I do not accept that the fasting window is a minor inconvenience. Adherence data on daily orals with timing requirements is consistently worse than weekly injections, and a drug you take imperfectly is a lower dose than the one on the box.
Adding the numbers, since they settle part of this. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.
mike.trainer_LA said:I do not accept that the fasting window is a minor inconvenience.
Coming at mike.trainer_LA’s question from a different direction. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsFollowing on from Dr.NateNeph — and this may be the naive question:
How much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly?
OP back with an update, since a thread like this is useless without one.
Update — I went back to the injectable. Not because the tablet did not work, but because the fasting window and my mornings were never going to agree.